Effects of Various Esketamine and Dexmedetomidine Doses on Long-Term Pain and Recovery After Scoliosis Correction Surgery

What this Trial Is About

Chronic postsurgical pain CPSP is pain that begins or worsens after surgery and lasts longer than three months, affecting up to 75% of patients after spinal correction surgery. This trial evaluates different doses of esketamine combined with dexmedetomidine as supplements to opioids for pain relief after scoliosis correction surgery. The study aims to see if higher esketamine doses can improve pain control and reduce chronic pain over time. Participants receive patient-controlled intravenous analgesia with varying doses of esketamine 50 mg, 100 mg, or 150 mg combined with a fixed dose of dexmedetomidine and sufentanil. The analgesia is delivered through programmed boluses and background infusion after surgery. This trial compares three groups receiving low, medium, or high esketamine doses to assess long-term outcomes after surgery. During the study, participants are monitored for chronic postsurgical pain at 3, 6, and 12 months after surgery. Researchers assess pain severity, sleep quality, depression levels, quality of life, and use of pain medications. This follow-up monitors the effectiveness of the treatments and overall recovery over one year, with safety and event-free survival also tracked.

Different Dose Esketamine and Dexmedetomidine for Supplemental Analgesia and Longterm Outcomes